GRIGUOLO, GAIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.987
AS - Asia 4.956
EU - Europa 2.782
SA - Sud America 849
AF - Africa 835
OC - Oceania 71
Continente sconosciuto - Info sul continente non disponibili 36
Totale 16.516
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.477
SG - Singapore 1.509
CN - Cina 913
IT - Italia 690
VN - Vietnam 600
HK - Hong Kong 555
BR - Brasile 539
DE - Germania 454
FI - Finlandia 307
BD - Bangladesh 199
IN - India 177
FR - Francia 155
GB - Regno Unito 118
PL - Polonia 103
SE - Svezia 94
NL - Olanda 90
IQ - Iraq 87
CA - Canada 85
RU - Federazione Russa 77
AR - Argentina 76
JP - Giappone 76
TR - Turchia 67
ID - Indonesia 65
PH - Filippine 65
MX - Messico 54
ZA - Sudafrica 54
BJ - Benin 48
SA - Arabia Saudita 48
AT - Austria 45
ES - Italia 43
TN - Tunisia 43
EC - Ecuador 42
PK - Pakistan 39
IE - Irlanda 35
CZ - Repubblica Ceca 34
UA - Ucraina 34
UZ - Uzbekistan 34
CI - Costa d'Avorio 33
AE - Emirati Arabi Uniti 32
MA - Marocco 32
MY - Malesia 31
PS - Palestinian Territory 31
VE - Venezuela 31
CH - Svizzera 30
KR - Corea 30
MK - Macedonia 30
CO - Colombia 29
AZ - Azerbaigian 28
JO - Giordania 28
KE - Kenya 28
LB - Libano 28
EG - Egitto 27
ET - Etiopia 27
RS - Serbia 27
HR - Croazia 26
JM - Giamaica 26
BA - Bosnia-Erzegovina 25
BG - Bulgaria 25
DO - Repubblica Dominicana 25
GT - Guatemala 25
IL - Israele 25
PE - Perù 25
SK - Slovacchia (Repubblica Slovacca) 25
UY - Uruguay 25
BB - Barbados 24
TT - Trinidad e Tobago 24
KZ - Kazakistan 23
ME - Montenegro 23
PA - Panama 23
TH - Thailandia 23
AL - Albania 22
AO - Angola 22
DZ - Algeria 22
ML - Mali 22
NI - Nicaragua 22
ZW - Zimbabwe 22
CR - Costa Rica 21
HN - Honduras 21
IR - Iran 21
MD - Moldavia 21
NZ - Nuova Zelanda 21
PY - Paraguay 21
BE - Belgio 20
BO - Bolivia 20
BS - Bahamas 20
BY - Bielorussia 20
CL - Cile 20
CW - ???statistics.table.value.countryCode.CW??? 20
EE - Estonia 20
GN - Guinea 20
HU - Ungheria 20
MR - Mauritania 20
MZ - Mozambico 20
NO - Norvegia 20
NP - Nepal 20
PT - Portogallo 20
RW - Ruanda 20
SN - Senegal 20
SO - Somalia 20
VC - Saint Vincent e Grenadine 20
Totale 15.643
Salva come PNG Salva come JPEG
Città #
Ashburn 1.285
Singapore 991
San Jose 792
Fairfield 574
Hong Kong 489
Chandler 384
Munich 331
Woodbridge 275
Helsinki 236
Houston 232
Cambridge 213
Ho Chi Minh City 196
Seattle 190
Beijing 182
Ann Arbor 175
Wilmington 175
Los Angeles 171
Hanoi 144
Boardman 127
New York 106
Santa Clara 101
Padova 93
Lauterbourg 77
San Diego 74
Council Bluffs 73
Buffalo 58
São Paulo 55
Princeton 53
Tokyo 53
Medford 52
Milan 50
Bytom 48
Cotonou 46
Rome 46
Chicago 43
Des Moines 43
Baghdad 40
Hefei 38
Padua 37
Warsaw 37
Da Nang 35
Orem 35
Chennai 34
London 34
Dallas 33
Abidjan 32
Montreal 31
Dublin 30
Roxbury 30
Tashkent 29
Turku 29
Guangzhou 26
Haiphong 26
Amman 25
Baku 25
Jeddah 25
Nairobi 25
Nuremberg 25
Bridgetown 24
Johannesburg 24
Addis Ababa 23
Frankfurt am Main 23
Managua 22
Pune 22
Vienna 22
Amsterdam 21
Bamako 21
Brooklyn 20
Conakry 20
Dakar 20
Harare 20
Montevideo 20
Nassau 20
Panama City 20
Podgorica 20
Kigali 19
Kingston 19
Kingstown 19
Luanda 19
Salt Lake City 19
Toronto 19
Willemstad 19
Castries 18
Guatemala City 18
Lusaka 18
Nanjing 18
Nouakchott 18
Phoenix 18
Antananarivo 17
Kampala 17
Minsk 17
Shanghai 17
Atlanta 16
Denver 16
Dushanbe 16
Falls Church 16
Maputo 16
Mexico City 16
Naples 16
Phnom Penh 16
Totale 9.713
Salva come PNG Salva come JPEG
Nome #
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors 370
ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis 367
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? 359
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study 318
Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: Analysis of 263 patients treated with standard therapy for stage I-III disease 302
Prognostic impact of proliferation for resected early stage ‘pure’ invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 290
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 286
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center 284
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer 282
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 279
Immune characterization of breast cancer metastases: Prognostic implications 274
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer 273
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer 267
Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives 264
A comprehensive profiling of the immune microenvironment of breast cancer brain metastases 260
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy 260
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 257
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial 253
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 249
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy 244
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome 243
Evolution of HER2-low expression from primary to recurrent breast cancer 243
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 239
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. 235
Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series 234
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study 233
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study 221
Olaparib for the treatment of breast cancer 219
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment 217
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer 209
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer 209
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience 207
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications 207
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors 206
The immune system and hormone-receptor positive breast cancer: Is it really a dead end? 203
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy 202
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial 200
The tumor microenvironment of primitive and metastatic breast cancer: Implications for novel therapeutic strategies 197
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 195
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer 194
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer 194
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer 192
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade 192
Erbb2 mrna expression and response to ado-trastuzumab emtansine (T-dm1) in her2-positive breast cancer 189
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 188
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology 188
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value 188
Fat grafting for breast cancer patients: From basic science to clinical studies 184
Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study 182
Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability? 179
A case of Hodgkin lymphoma in a patient with a history of bone pain and an initial diagnosis of chronic osteomyelitis 170
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype 170
Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases 169
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival 160
Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real-world data from a multicentric European cohort 159
PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort study 156
Cardiac Safety of Adjuvant Trastuzumab and Paclitaxel for HER2+ early breast cancer patients published in Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM) 25-27 October, 2019 - Rome, Italy Abstracts 156
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis 155
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer 155
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 150
Radiological response of leptomeningeal metastases according to revised RANO criteria is associated with overall survival in breast cancer patients 144
Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer 139
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases 138
Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials 134
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade 130
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors 128
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials 127
Independent validation of the PAM50-based Chemo-Endocrine Score in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant therapy 126
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer 124
Olaparib for advanced breast cancer 123
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer 120
Gene expression profiling in a retrospective real-world cohort of breast cancer brain metastases and paired primary tumors identifies biological changes with potential therapeutic implications 120
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer 119
Prognosis and biological characteristics of ER-low metastatic breast cancer: results from a multicenter cohort and the TONIC trial 117
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 113
Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data 110
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review 104
A systematic review of contemporary phase I trials in patients with lymphoma 101
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 97
Use of electronic administrative databases to measure quality indicators of breast cancer care: Experience of five regional oncology networks in Italy 96
The Impact of COVID-19 on Treatment Practices for Patients With Early Breast Cancer: A Cross-Sectional Study From a Large Cancer Center in Italy 83
Temporal evolution of breast cancer brain metastases treatments and outcomes 71
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer 70
Exceptional responses to systemic treatment in metastatic breast cancer: clinical features and long-term outcomes 70
BET inhibitors as potential anticancer agents 70
Impact of germline BRCA1/2 status on outcomes for patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a systematic review and meta-analysis 58
Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications 49
Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab 46
Health networking on cancer in the European Union: a ‘green paper’ by the EU Joint Action on Networks of Expertise (JANE) 44
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis 41
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study 35
Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohort 33
Omitting anthracyclines for the adjuvant treatment of patients with triple-negative breast cancer: A non-inferiority meta-analysis 30
A 3D morphogenetic blueprint for metastatic outgrowth in breast cancer 27
Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer 20
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2 8
Evolution of ER-cut-off definition in clinical trials for triple negative breast cancer: trends and patterns over 15 years 6
Long-term outcome of isolated locoregional (ILRR) breast cancer (BC) recurrence: a large retrospective Mono-institutional study 6
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study 5
Totale 16.709
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.226
article - articoli 46.226
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 92.452
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202129 0 0 0 0 0 0 0 0 0 0 0 29
2021/2022850 50 62 83 46 103 81 75 49 46 38 54 163
2022/2023742 122 93 40 106 76 80 26 47 93 10 41 8
2023/2024811 44 60 55 43 44 75 50 255 15 41 56 73
2024/20252.605 7 164 85 90 196 151 250 291 271 148 384 568
2025/20269.849 471 608 1.292 1.511 898 431 1.409 821 986 676 633 113
Totale 16.709